[go: up one dir, main page]

ZA200201249B - Solid lipid formulations. - Google Patents

Solid lipid formulations. Download PDF

Info

Publication number
ZA200201249B
ZA200201249B ZA200201249A ZA200201249A ZA200201249B ZA 200201249 B ZA200201249 B ZA 200201249B ZA 200201249 A ZA200201249 A ZA 200201249A ZA 200201249 A ZA200201249 A ZA 200201249A ZA 200201249 B ZA200201249 B ZA 200201249B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical composition
composition according
fatty acid
mixtures
acid ester
Prior art date
Application number
ZA200201249A
Other languages
English (en)
Inventor
Passchier Christiaan De Smidt
Hans Lengsfeld
David Macfarland Small
Joseph Tardio
Hadvary Paul Schmid Marce Hans
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200201249(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200201249B publication Critical patent/ZA200201249B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA200201249A 1999-09-13 2002-02-13 Solid lipid formulations. ZA200201249B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99118179 1999-09-13

Publications (1)

Publication Number Publication Date
ZA200201249B true ZA200201249B (en) 2003-07-30

Family

ID=8238989

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200201249A ZA200201249B (en) 1999-09-13 2002-02-13 Solid lipid formulations.

Country Status (36)

Country Link
US (1) US6703369B1 (xx)
EP (1) EP1216048B1 (xx)
JP (1) JP4217017B2 (xx)
KR (1) KR100523879B1 (xx)
CN (1) CN1197554C (xx)
AR (1) AR025609A1 (xx)
AT (1) ATE285783T1 (xx)
AU (1) AU769016B2 (xx)
BR (1) BRPI0013940B1 (xx)
CA (1) CA2383036C (xx)
CO (1) CO5210857A1 (xx)
CZ (1) CZ301844B6 (xx)
DE (1) DE60017156T2 (xx)
EG (1) EG24225A (xx)
ES (1) ES2233444T3 (xx)
GC (1) GC0000259A (xx)
HK (1) HK1049798B (xx)
HR (1) HRP20020206B1 (xx)
HU (1) HU229037B1 (xx)
IL (2) IL148570A0 (xx)
JO (1) JO2300B1 (xx)
MA (1) MA26817A1 (xx)
ME (1) ME00675B (xx)
MX (1) MXPA02002662A (xx)
MY (1) MY127430A (xx)
NO (1) NO328889B1 (xx)
NZ (1) NZ517396A (xx)
PE (1) PE20010661A1 (xx)
PL (1) PL199869B1 (xx)
PT (1) PT1216048E (xx)
RS (1) RS50373B (xx)
RU (1) RU2248218C2 (xx)
SI (1) SI1216048T1 (xx)
TR (1) TR200200605T2 (xx)
WO (1) WO2001019378A2 (xx)
ZA (1) ZA200201249B (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
KR100572785B1 (ko) 2000-07-28 2006-04-19 에프. 호프만-라 로슈 아게 신규한 약학 조성물
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
DE10251963A1 (de) * 2002-11-08 2004-05-19 Lts Lohmann Therapie-Systeme Ag Transmucosale pharmazeutische Darreichungsform
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
MXPA05009469A (es) * 2003-03-04 2005-12-12 Nostrum Pharmaceuticals Inc Formulacion de liberacion controlada que contiene un material hidrofobico como agente de liberacion prolongada.
FI20045076L (fi) * 2004-03-15 2005-09-16 Bioferme Oy Funktionaalinen elintarvike
WO2006046623A1 (ja) * 2004-10-25 2006-05-04 Japan Tobacco Inc. 溶解性及び安定性の改善された固形製剤及びその製造方法
KR100669497B1 (ko) * 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
CA2626234A1 (en) * 2005-12-22 2007-06-28 Teva Pharmaceutical Industries Ltd. Compressed solid dosage forms with drugs of low solubility and process for making the same
EP1808163A1 (en) * 2005-12-22 2007-07-18 Teva Pharmaceutical Industries Ltd. Compressed solid dosage forms with drugs of low solubility and process for making the same
KR101252635B1 (ko) 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
KR100903504B1 (ko) * 2007-05-18 2009-06-17 강태용 비라칸사스 열매 추출물질을 포함하는 기능식품 및 체중 감소제
JP2010536798A (ja) * 2007-08-17 2010-12-02 テバ ファーマシューティカル インダストリーズ リミティド 難溶性薬物の生体利用率を制御するための方法及び組成物
PL2036575T3 (pl) * 2007-09-12 2011-02-28 Mader S R L Kompozycje farmaceutyczne do stosowania doustnie w leczeniu pacjentów dotkniętych otyłością
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
US8309107B2 (en) 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
BRPI0901602B8 (pt) 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
UA107369C2 (en) 2010-02-01 2014-12-25 Lab Bago S A Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
EP2486805A1 (en) * 2011-02-11 2012-08-15 Puratos N.V. An emulsion whippable at room-temperature
PL2671455T3 (pl) * 2011-04-14 2017-10-31 J Oil Mills Inc Frakcjonowany olej palmowy oraz kompozycja oleju i produkt spożywczy ją zawierający
CN102552168B (zh) * 2012-01-31 2013-08-07 杭州华东医药集团生物工程研究所有限公司 一种含有奥利司他的药物组合物及其制备方法
GB2501535A (en) 2012-04-26 2013-10-30 Sony Corp Chrominance Processing in High Efficiency Video Codecs
AU2013267359C1 (en) * 2012-05-31 2016-09-29 Allergan pharmaceuticals International Ltd. Formulations and methods for vaginal delivery of antiprogestins
CA2923838A1 (en) 2013-10-28 2015-05-07 Nestec S.A. Monoacylglycerols for use in conjunction with a lipase inhibitor and/or diets low in fat and/or calories
CN115105476B (zh) * 2021-03-23 2023-11-14 山东新时代药业有限公司 一种奥利司他冻干口服制剂及其制备工艺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
FR2710264B1 (fr) * 1993-09-21 1995-12-08 Rocher Yves Biolog Vegetale Utilisation pour le traitement des peaux mixtes d'une quantité efficace de substances actives.
WO1998024607A1 (en) * 1996-12-04 1998-06-11 Pincott James S Process and apparatus for making crumb rubber from scrap tyres
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
CZ295567B6 (cs) 1997-02-05 2005-08-17 F. Hoffmann-La Roche Ag Tetrahydrolipstatin pro výrobu orálního farmaceutického prostředku pro ošetřování typu II diabetes mellitus
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
BR9912979B1 (pt) * 1998-08-14 2010-09-21 composição farmacêutica administrável oralmente, tablete de mascar, cápsula e uso de chitosan.
KR20010079635A (ko) 1998-08-14 2001-08-22 프리돌린 클라우스너, 롤란드 비. 보레르 리파아제 저해제를 함유하는 약학 조성물
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas

Also Published As

Publication number Publication date
GC0000259A (en) 2006-11-01
AR025609A1 (es) 2002-12-04
KR20020060177A (ko) 2002-07-16
HK1049798A1 (en) 2003-05-30
MXPA02002662A (es) 2002-07-30
PT1216048E (pt) 2005-04-29
JP4217017B2 (ja) 2009-01-28
KR100523879B1 (ko) 2005-10-26
BRPI0013940B1 (pt) 2016-06-21
NO20021205D0 (no) 2002-03-12
CZ20021277A3 (cs) 2003-04-16
IL148570A (en) 2007-03-08
RU2002107450A (ru) 2004-01-10
CA2383036C (en) 2006-01-10
JP2003509373A (ja) 2003-03-11
EG24225A (en) 2008-11-10
DE60017156D1 (de) 2005-02-03
HRP20020206B1 (en) 2011-02-28
MY127430A (en) 2006-11-30
EP1216048B1 (en) 2004-12-29
MEP90908A (en) 2011-12-20
PE20010661A1 (es) 2001-06-25
HUP0202762A3 (en) 2005-04-28
CA2383036A1 (en) 2001-03-22
RS50373B (sr) 2009-11-10
WO2001019378A3 (en) 2001-05-10
CZ301844B6 (cs) 2010-07-07
NO328889B1 (no) 2010-06-07
NZ517396A (en) 2003-10-31
WO2001019378A2 (en) 2001-03-22
IL148570A0 (en) 2002-09-12
HK1049798B (zh) 2005-08-05
CO5210857A1 (es) 2002-10-30
NO20021205L (no) 2002-03-12
RU2248218C2 (ru) 2005-03-20
CN1197554C (zh) 2005-04-20
ATE285783T1 (de) 2005-01-15
HUP0202762A2 (hu) 2003-01-28
ME00675B (me) 2011-12-20
TR200200605T2 (tr) 2002-08-21
CN1373659A (zh) 2002-10-09
AU769016B2 (en) 2004-01-15
MA26817A1 (fr) 2004-12-20
DE60017156T2 (de) 2006-01-05
YU13602A (sh) 2006-01-16
HU229037B1 (en) 2013-07-29
ES2233444T3 (es) 2005-06-16
JO2300B1 (en) 2005-09-12
PL199869B1 (pl) 2008-11-28
SI1216048T1 (en) 2005-06-30
AU7517700A (en) 2001-04-17
HRP20020206A2 (en) 2004-04-30
US6703369B1 (en) 2004-03-09
BR0013940A (pt) 2002-05-14
PL356154A1 (en) 2004-06-14
EP1216048A2 (en) 2002-06-26

Similar Documents

Publication Publication Date Title
CA2383036C (en) Solid lipid formulations
US8343543B2 (en) Lipase inhibiting composition
CA2383916C (en) Dispersion formulations containing lipase inhibitors
AU2002257817A1 (en) Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester
JP2004531548A (ja) ナトリウムフェニトイン剤形の製造のための圧縮方法